FDA Approved Semaglutide: The Top Weight Loss Drug of 2025
Transforming Obesity Management: The Semaglutide Revolution As obesity prevalence continues to escalate globally, the demand for efficacious and safe pharmacological interventions has intensified. Semaglutide, an FDA approved glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as the preeminent weight loss drug of 2025, revolutionizing the therapeutic landscape with unprecedented clinical efficacy and safety profiles. This article … Read more